Sep 04, 2024 9:15am EDT Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series
Aug 19, 2024 8:45am EDT Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer
Aug 14, 2024 8:35am EDT Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
Jul 24, 2024 8:30am EDT Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study
Jun 20, 2024 8:30am EDT Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds
Jun 13, 2024 8:00am EDT Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain
May 28, 2024 8:00am EDT Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting
May 20, 2024 9:15am EDT Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target
May 14, 2024 4:15pm EDT Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update
